Catching you up on the week of March 2–8, 2026: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
PharmAla Biotech Holdings Inc. (MDMA): PharmAla signs MDMA supply-and-data deal with Nautilus Sanctuary for U.S. first-responder PTSD trial
PharmAla Biotech signed a supply-and-data agreement with Nautilus Sanctuary to provide LaNeo MDMA for an open-label Phase 2 U.S. trial of MDMA-assisted therapy in frontline healthcare workers and first responders with post-traumatic stress and adjustment disorder. In exchange, PharmAla receives a perpetual, non-exclusive license to the trial data for regulatory and commercial use in any jurisdiction. The structure lets PharmAla accumulate clinical data assets while supplying drug product.
Source: bnnbloomberg.ca
Clearmind Medicine Inc. (CMND): Clearmind's CMND-100 alcohol-use-disorder trial advances after DSMB clearance
Clearmind Medicine said its independent Data and Safety Monitoring Board reviewed the accumulated safety data and cleared the CMND-100 Phase I/IIa alcohol-use-disorder trial to proceed to its next stage. The decision followed the positive second-cohort safety results reported in February. Advancing past the DSMB checkpoint keeps the non-hallucinogenic MEAI-based candidate moving through early clinical development.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.